ImpediMed Limited (IPD.AX)
ImpediMed Limited operates in the Medical - Devices industry of the Healthcare sector, headquartered in Carlsbad, CA, US. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $10.5M. Its beta of 1.09 implies it has historically moved more than the broad market.
Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
ImpediMed Limited is most often compared with the following Healthcare names: